// App-Quantinova.ai

TPS4150 : A phase 2, open-label, multicenter study of durvalumab (MEDI4736) tremelimumab in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC): ALPS.

Researchers

Presenter

  • Eileen Mary O'Reilly

Principal Investigators

  • Do-Youn Oh

  • Myung Ah Lee

  • Neesha Dhani

  • Jon Armstrong

  • Riccardo Belli

  • Salvatore Ferro

  • Yong Ben

Medical Centers

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Princess Margaret Cancer Center, Toronto, ON, Canada

  • AstraZeneca, Alderley Park, United Kingdom

  • AstraZeneca, Gaithersburg, MD

Locations

  • United States

  • Canada

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Genetic Disorder

Disease

  • Pancreas ductal adenocarcinoma

  • Autoimmune lymphoproliferative syndromes

Biomarkers

  • Programmed death-ligand 1

Drug/Treatment

  • Adrucil injection

  • Ticilimumab

  • Gemcitabine

  • Durvalumab

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

  • Multicenteric

Phase

  • II

Study Id's

  • NCT02558894

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved